Company intelligence
Lavior Pharma Inc
Here to Heal
About Lavior Pharma Inc
Lavior® Pharma: Advanced Botanical-Based, Bio-Engineered Solutions for Diabetic Wound and Skincare Lavior® is redefining diabetic wound care through the development of advanced, botanical-based medical devices designed to treat chronic, hard-to-heal wounds and skin conditions. As the only company solely dedicated to the therapeutic skincare needs of the diabetic population, Lavior® delivers clinically proven solutions aimed at improving outcomes and reducing the risk of complications, including amputation. Our proprietary formulations, based on the Inula AGS-RIED botanical species, are engineered using pharmaceutical-grade ingredients and supported by over 15 years of scientific research and clinical trials. Lavior® products are FDA-compliant and manufactured to the highest safety and efficacy standards, consistently outperforming conventional treatments in clinical settings. Indicated for diabetic foot ulcers, pressure injuries, burns, eczema, fungal and bacterial infections, and other dermatological complications, the Lavior® product line is designed to integrate seamlessly into wound care protocols across outpatient, inpatient, and home care environments. Lavior® is committed to advancing wound care with innovative medical solutions that help clinicians improve healing, prevent amputations, and elevate patient quality of life.
Verified activity
Signals from Lavior Pharma Inc
13 published signals
Customers & Market
Lavior Pharma Inc offers clinical-tier products available through McKesson and Cardinal Health, reimbursable under A6248, backed by a published randomized controlled trial and multiple independent case studies.
Reported by Gilad Savion
Products & Services
Lavior Pharma Inc launched the Post-Surgical Skin Barrier Gel, reimbursable under A6250, manufactured with botanically derived hydrogel technology, designed to support the wound from day one post-procedure through complete scar remodeling.
Reported by Gilad Savion
Research & Knowledge
Lavior Pharma Inc published the RENEW Study in the Journal of Wound Care evaluating Lavior's Diabetic Wound Therapy against SoloSite, a standard hydrogel from Smith+Nephew in a prospective randomized controlled trial.
Reported by Ashlyn Tapley
Strategy & Corporate Development
Lavior Pharma Inc achieved WBENC certification.
Reported by Lavior Pharma Inc
Presence & Recognition
Lavior Pharma Inc built a physician advisory board from day one.
Reported by Lavior Pharma Inc
Strategy & Corporate Development
Lavior Pharma Inc expanded its retail availability on Amazon, Walmart, and Target.
Reported by Lavior Pharma Inc
Strategy & Corporate Development
Lavior Pharma Inc expanded its distribution through McKesson, Cardinal Health, PRISM, Byram, and VA facilities through Lovell.
Reported by Lavior Pharma Inc
Strategy & Corporate Development
Lavior Pharma Inc received the SBDC Business Excellence Award.
Reported by Lavior Pharma Inc
Research & Knowledge
Lavior Pharma Inc published research in Molecular Medicine detailing the molecular mechanisms underlying collagen organization during wound healing and the influence of inflammatory and remodeling phases on scar quality.
Reported by J David Warren
Research & Knowledge
Lavior Pharma Inc authored a case study booklet documenting outcomes across more than a dozen wound types authored by independent physicians.
Reported by Gilad Savion
Research & Knowledge
Lavior Pharma Inc published a randomized controlled trial in a peer-reviewed journal.
Reported by Gilad Savion
Presence & Recognition
Lavior Pharma Inc presented at six major wound care conferences in the last year.
Reported by Gilad Savion
Presence & Recognition
Lavior Pharma Inc is the number one seller in diabetic wound care on Amazon in the United States.
Reported by Gilad Savion